Following NAD Challenge, Factor Nutrition Permanently Discontinues Claim that Focus Factor is “America’s #1 Brain Health Supplement”

 

For Immediate Release 

Contact: Abby Hills, Director of Communications, BBB National Programs, 301.412.7769 / ahills@bbbnp.org 

 

NAD Finds No Reasonable Basis for Proposed Modified Claim, “America’s #1 Clinically Studied and Patented Brain Health Formula" 

 

New York, NY – May 6, 2020 – The BBB National Programs National Advertising Division (NAD) recommended that Factor Nutrition, LLC discontinue the claim that its Focus Factor brain health supplement is “America’s #1 Clinically Studied and Patented Brain Health Formula,” following a challenge by Quincy BioScience, Inc., maker of Prevagen brain health dietary supplement. 

NAD is an investigative unit of the advertising industry’s system of self-regulation and is a division of the BBB National Programs’ self-regulatory and dispute resolution programs. 

During the course of the proceeding, Factor Nutrition agreed to permanently discontinue the challenged claim “America’s #1 Brain Health Supplement,” which appeared on product packaging, labeling and in internet advertising. NAD, relying on the advertiser’s representation that the claim has been permanently discontinued, did not review the claim on its merits. The voluntarily discontinued claim will be treated, for compliance purposes, as though NAD recommended its discontinuance and the advertiser agreed to comply. 

The advertiser proposed a modification of its claim to read: “America’s #1 Clinically Studied and Patented Brain Health Formula,” and NAD assessed whether the evidence in the record was sufficient to substantiate the claim. 

First, NAD determined that the evidence in the record was insufficient to support the health-related product efficacy claim that Focus Factor is “America’s #1 Clinically Studied . . . Brain Health Supplement.” The evidence in the record demonstrated that other brain health supplements (including Prevagen) outsell Focus Factor, however, there was limited evidence in the record regarding which of those products had been clinically studied or the reliability of those studies. NAD noted that in order to support its claim the advertiser would have needed to show that, for any products that outsell Focus Factor, testing on those products is lacking or is insufficiently reliable to demonstrate any brain health benefits.  

Further, with regard to the latter portion of the claim, that Focus Factor is “America’s #1 . . . Patented Brain Health Formula,” the advertiser argued that the claim is supported because Focus Factor has a patent on the product’s formula covering “brain health and mental performance,” whereas the challenger does not hold a patent on Prevagen’s finished product but, rather, only on certain ingredients in its product. While the advertiser’s Focus Factor supplement has a 2012 patent, NAD noted that the product’s Supplement Facts lists ingredients not mentioned in the patent’s list of ingredients – Vitamins A, C and D, and Riboflavin – calling into question whether its patent covers the entire finished formula. NAD also determined that even if it is literally true that Focus Factor is the #1 selling product that has (1) a patent on its finished formula and (2) a patent specifically for brain health, consumers would be unlikely to make the nuanced distinction between the advertiser’s product and the challenger’s (and other) brain health supplements with patented key ingredients. Rather, consumers would likely still take away the overarching – but unsupported message – that Focus Factor is America’s #1 selling brain health supplement that is also patented. 

For these reasons, NAD determined that the advertiser did not provide a reasonable basis for its proposed modified claim that Focus Factor is “America’s #1 Clinically Studied and Patented Brain Health Formula,” and recommended that the claim be discontinued.  

In its advertiser’s statement, Factor Nutrition was disappointed with certain of NAD’s findings, but agreed to comply with NAD’s recommendations.   

### 

About the National Advertising Division: National Advertising Division (NAD), a division of BBB National Programs, provides independent self-regulation overseeing the truthfulness of advertising across the U.S. NAD reviews national advertising in all media and its decisions set consistent standards for truth and accuracy.  

About BBB National Programs: BBB National Programs fosters trust, innovation, and competition in the marketplace through the development and delivery of cost-effective, third-party self-regulation, dispute resolution and other programs. BBB National Programs is the home of industry self-regulatory and dispute resolution programs designed to resolve business issues and advance shared objectives by responding to marketplace concerns to create a better customer experience. To learn more about industry self-regulation, please visit: BBBNP.org

 

Latest News

Decision

Following NAD Inquiry, L’Oréal Modifies Disclosures to Clarify that Content on Sites May be Advertising

Following an inquiry by the National Advertising Division (NAD), L’Oréal USA made immediate modifications to three L’Oréal-owned websites, Makeup.com, Skincare.com, and Hair.com, to enhance and make it clear that the content is written by or on behalf of L’Oréal. The...
Read more
Decision

Luxury Mattress Manufacturer, The Saatva Company, Should Exercise Caution Making Claims Based on Third-Party Ratings and Rankings

Following a challenge by Casper Sleep Inc., the National Advertising Division (NAD) found there no evidence demonstrating that luxury mattress manufacturer Whitestone Home Furnishings, LLC d/b/a The Saatva Company has material connections to third-party websites that...
Read more
Decision

NAD Recommends Amerisleep Discontinue or Modify “Native Advertising” Websites SleepJunkie.org and SavvySleeper.org

The National Advertising Division (NAD) determined that two mattress ranking and review websites, SleepJunkie.org and SavvySleeper.org, owned by the mattress manufacturer Amerisleep, LLC, may appear independent to consumers and...

Read more
Decision

NAD Refers Advertising Claims for Little Spoon Baby Food to FDA and FTC for Further Review After Company Declines to Comply with NAD’s Recommendations

The National Advertising Division (NAD) has referred online advertising claims made by Little Spoon, Inc. for its Little Spoon Baby Food to the Federal Trade Commission and the U.S. Food and Drug Administration for further review after the company declined to comply with...
Read more